Search Results - "Jayson, Gordon C."

Antiangiogenic therapy in oncology: current status and future directions by Jayson, Gordon C, Prof, Kerbel, Robert, Prof, Ellis, Lee M, Prof, Harris, Adrian L, Prof

“…Summary Angiogenesis, the formation of new blood vessels from pre-existing vessels, has been validated as a target in several tumour types through randomised…”
Get full text

Ovarian cancer by Jayson, Gordon C, Prof, Kohn, Elise C, MD, Kitchener, Henry C, Prof, Ledermann, Jonathan A, Prof

“…Summary Epithelial ovarian cancer is the commonest cause of gynaecological cancer-associated death. The disease typically presents in postmenopausal women,…”
Get full text

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial by Kehoe, Sean, Prof, Hook, Jane, MRCP, Nankivell, Matthew, MSc, Jayson, Gordon C, Prof, Kitchener, Henry, Prof, Lopes, Tito, MD, Luesley, David, Prof, Perren, Timothy, Prof, Bannoo, Selina, MSc, Mascarenhas, Monica, PhD, Dobbs, Stephen, MD, Essapen, Sharadah, MD, Twigg, Jeremy, MD, Herod, Jonathan, MD, McCluggage, Glenn, Prof, Parmar, Mahesh, Prof, Swart, Ann-Marie, Prof

“…Summary Background The international standard of care for women with suspected advanced ovarian cancer is surgical debulking followed by platinum-based…”
Get full text

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial by Oza, Amit M, Prof, Cook, Adrian D, MSc, Pfisterer, Jacobus, Prof, Embleton, Andrew, MSc, Ledermann, Jonathan A, Prof, Pujade-Lauraine, Eric, Prof, Kristensen, Gunnar, Prof, Carey, Mark S, MD, Beale, Philip, MD, Cervantes, Andrés, Prof, Park-Simon, Tjoung-Won, Prof, Rustin, Gordon, Prof, Joly, Florence, Prof, Mirza, Mansoor R, MD, Plante, Marie, MD, Quinn, Michael, Prof, Poveda, Andrés, MD, Jayson, Gordon C, Prof, Stark, Dan, MD, Swart, Ann Marie, Prof, Farrelly, Laura, MSc, Kaplan, Richard, Prof, Parmar, Mahesh K B, Prof, Perren, Timothy J, Prof

“…Summary Background The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer with the addition of bevacizumab to…”
Get full text

The role of vascular endothelial growth factor inhibitors in the treatment of epithelial ovarian cancer by Murphy, Alexander D., Morgan, Robert D., Clamp, Andrew R., Jayson, Gordon C.

“…Advanced epithelial ovarian, fallopian tube and primary peritoneal cancers (EOC) are a leading cause of gynaecological cancer-associated mortality and…”
Get full text

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial by Ledermann, Jonathan A, Prof, Embleton, Andrew C, MSc, Raja, Fharat, BMBCh, Perren, Timothy J, Prof, Jayson, Gordon C, Prof, Rustin, Gordon J S, Prof, Kaye, Stan B, Prof, Hirte, Hal, MD, Eisenhauer, Elizabeth, Prof, Vaughan, Michelle, MB, Friedlander, Michael, Prof, González-Martín, Antonio, MD, Stark, Daniel, MD, Clark, Elizabeth, BSc, Farrelly, Laura, MSc, Swart, Ann Marie, Prof, Cook, Adrian, MSc, Kaplan, Richard S, Prof, Parmar, Mahesh K B, Prof

“…Summary Background Angiogenesis is a validated clinical target in advanced epithelial ovarian cancer. Cediranib is an oral antiangiogenic vascular endothelial…”
Get full text

Antiangiogenic therapy—evolving view based on clinical trial results by Jayson, Gordon C., Hicklin, Daniel J., Ellis, Lee M.

“…Antiangiogenic therapies have secured a role in the treatment of multiple cancers. However, the success of this targeted therapy is not as great as originally…”
Get full text

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial by Rustin, Gordon JS, Prof, van der Burg, Maria EL, MD, Griffin, Clare L, MSc, Guthrie, David, FRCR, Lamont, Alan, FRCR, Jayson, Gordon C, Prof, Kristensen, Gunnar, MD, Mediola, César, MD, Coens, Corneel, MSc, Qian, Wendi, PhD, Parmar, Mahesh KB, Prof, Swart, Ann Marie, Dr

“…Summary Background Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC…”
Get full text

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity by Nelson, Louisa, Tighe, Anthony, Golder, Anya, Littler, Samantha, Bakker, Bjorn, Moralli, Daniela, Murtuza Baker, Syed, Donaldson, Ian J., Spierings, Diana C. J., Wardenaar, René, Neale, Bethanie, Burghel, George J., Winter-Roach, Brett, Edmondson, Richard, Clamp, Andrew R., Jayson, Gordon C., Desai, Sudha, Green, Catherine M., Hayes, Andy, Foijer, Floris, Morgan, Robert D., Taylor, Stephen S.

“…High-grade serous ovarian carcinoma is characterised by TP53 mutation and extensive chromosome instability (CIN). Because our understanding of CIN mechanisms…”
Get full text

Ovarian Cancer Cell Heparan Sulfate 6-O-Sulfotransferases Regulate an Angiogenic Program Induced by Heparin-binding Epidermal Growth Factor (EGF)-like Growth Factor/EGF Receptor Signaling by Cole, Claire L., Rushton, Graham, Jayson, Gordon C., Avizienyte, Egle

“…Heparan sulfate (HS) is a component of cell surface and extracellular matrix proteoglycans that regulates numerous signaling pathways by binding and activating…”
Get full text

First-Line Management of Advanced High-Grade Serous Ovarian Cancer by Mahmood, Reem D., Morgan, Robert D., Edmondson, Richard J., Clamp, Andrew R., Jayson, Gordon C.

“…Purpose of Review Epithelial ovarian cancer is a disease that encompasses a number of histologically and molecularly distinct entities; the most prevalent…”
Get full text

Experimentally-derived functional form for a population-averaged high-temporal-resolution arterial input function for dynamic contrast-enhanced MRI by Parker, Geoff J.M., Roberts, Caleb, Macdonald, Andrew, Buonaccorsi, Giovanni A., Cheung, Sue, Buckley, David L., Jackson, Alan, Watson, Yvonne, Davies, Karen, Jayson, Gordon C.

“…Rapid T1‐weighted 3D spoiled gradient‐echo (GRE) data sets were acquired in the abdomen of 23 cancer patients during a total of 113 separate visits to allow…”
Get full text

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer by Morgan, Robert D., Clamp, Andrew R., Evans, D. Gareth R., Edmondson, Richard J., Jayson, Gordon C.

“…Purpose Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the…”
Get full text

Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer by Jayson, Gordon C., Zhou, Cong, Backen, Alison, Horsley, Laura, Marti-Marti, Kalena, Shaw, Danielle, Mescallado, Nerissa, Clamp, Andrew, Saunders, Mark P., Valle, Juan W., Mullamitha, Saifee, Braun, Mike, Hasan, Jurjees, McEntee, Delyth, Simpson, Kathryn, Little, Ross A., Watson, Yvonne, Cheung, Susan, Roberts, Caleb, Ashcroft, Linda, Manoharan, Prakash, Scherer, Stefan J., del Puerto, Olivia, Jackson, Alan, O’Connor, James P. B., Parker, Geoff J. M., Dive, Caroline

“…Oncological use of anti-angiogenic VEGF inhibitors has been limited by the lack of informative biomarkers. Previously we reported circulating Tie2 as a…”
Get full text

Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging by Jackson, Alan, O'Connor, James P B, Parker, Geoff J M, Jayson, Gordon C

“…This article reviews the application of dynamic contrast-enhanced magnetic resonance imaging in both clinical studies and early-phase trials of angiogenesis…”
Get full text

Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England by Flaum, Nicola, Morgan, Robert D, Burghel, George J, Bulman, Michael, Clamp, Andrew R, Hasan, Jurjees, Mitchell, Claire L, Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R, Crosbie, Emma J, Edmondson, Richard J, Wallace, Andrew J, Jayson, Gordon C, Lalloo, Fiona I, Harkness, Elaine F, Evans, D Gareth R

“…Poly(ADP-ribose) polymerase (PARP) inhibitors improve survival in BRCA-mutant high-grade serous ovarian carcinoma. As a result, germline and somatic BRCA1/2…”
Get full text

The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors by Carucci, Margherita, Clamp, Andrew, Zhou, Cong, Hurt, Chris, Glasspool, Rosalind, Monaghan, Phillip J, Thirkettle, Sally, Wheatley, Michael, Mahmood, Madia, Narasimham, Monica, Cox, Tracy, Morrison, Hilary, Campbell, Susan, Nelson, Annmarie, Holland-Hart, Daniella, Hopewell-Kelly, Noreen, Thomas, Abin, Porter, Catharine, Slusarczyk, Magdalena, Irving, Alys, Dive, Caroline, Adams, Richard, Jayson, Gordon C

“…Anti-angiogenic, VEGF inhibitors (VEGFi) increase progression-free survival (PFS) and, in some cases, overall survival in many solid tumours. However, their…”
Get full text

Cancer patterns and association with mortality and renal outcomes in non-dialysis dependent chronic kidney disease: a matched cohort study by Chinnadurai, Rajkumar, Flanagan, Emma, Jayson, Gordon C, Kalra, Philip A

“…Cancer in patients with chronic kidney disease (CKD) is an added burden to their overall morbidity and mortality. Cancer can be a cause or an effect of CKD. In…”
Get full text

Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregivers by Sowerbutts, Anne Marie, Lal, Simon, Sremanakova, Jana, Clamp, Andrew R, Jayson, Gordon C, Teubner, Antje, Hardy, Lisa, Todd, Chris, Raftery, Anne-Marie, Sutton, Eileen, Morgan, Robert D, Vickers, Alexander J, Burden, Sorrel

“…Malnutrition is a problem in advanced cancer, particularly ovarian cancer where malignant bowel obstruction (MBO) is a frequent complication. Parenteral…”
Get full text

Home Parenteral Nutrition in Patients with Advanced Cancer: Quality Outcomes from a Centralized Model of Care Delivery by Kopczynska, Maja, Teubner, Antje, Abraham, Arun, Taylor, Michael, Bond, Ashley, Clamp, Andrew, Wight, Rebecca, Salih, Zena, Hasan, Jurjees, Mitchell, Claire, Jayson, Gordon C, Lal, Simon

“…Lack of expertise in home parenteral nutrition (HPN) management has been reported as a barrier to its initiation in patients with advanced cancer (AC), and…”
Get full text